Tissue Targeted Medicines, Designed In Vivo.
We design tissue-specific medicines in living systems from the start by combining high-throughput in-vivo studies with AI-guided protein design.
Making Tissue Specificity Tractable through In Vivo Optimization
Knowledge of biological targets and lessons from clinical data have revealed compelling opportunities for therapeutic interventions. Yet, the ability to deliver medicines sufficiently and specifically to the site of action remains one of the greatest challenges in realizing transformational medicines.
Powerful new computational and experimental tools for protein design are held back by the requirement to evaluate molecules in reductionist in vitro assays. But only in vivo data can truly predict how a drug navigates a living system.
Manifold has created an in vivo biologics design platform that empowers creation of medicines that go to specific areas in the body. This is enabled by a proprietary protein barcoding technology, mCodes, that allows tagging and measuring hundreds of candidates in a single animal model; allowing for broad collection of data about the candidate's pharmacokinetics and biodistribution. This rich in vivo data feeds into our AI-enabled protein design platform and allows us to rapidly iterate towards the candidates with the most optimal in vivo profiles.
With the ability to engineer biologics in vivo, Manifold is uniquely enabled to pursue therapeutic opportunities where specific targeting is the challenge to a compelling product profile.
Scalable, Parallel In Vivo Discovery with mDesign™
Our mDesign™ platform integrates high-throughput in vivo screening with AI-powered protein design to enable the discovery of tissue-targeted therapeutics. Traditional protein engineering relies heavily on iterative optimization in in vitro assays. Manifold Bio has solved the in vivo data generation problem with the invention of mCodes™, a proprietary tagged multiplexing technology to evaluate distribution of over 100 antibody designs at a time in a single animal. The resulting data guides our molecular optimization process directly in living systems. We are using our platform to advance several candidates toward development.
AI-Guided Protein Design
Powered by In Vivo Data
Our mCodes technology tracks hundreds of drug candidates in parallel animal studies, generating vast amounts of in vivo data. This powers a virtuous AI cycle: the data teaches the AI to design better molecules, which are then tested to generate new data, further improving the AI. The result is a rapidly expanding map of molecular space and a stream of optimized leads, seamlessly connecting AI predictions to real-world performance.
AI-Guided Design (Libraries + Display Technologies)
In-Vivo Data Generation at Scale
Expanding Proprietary Dataset
Shuttled Therapeutics for Neuromedicine and Beyond
A renaissance has begun in neuroscience with recent clinical data supporting a number of promising targets for therapeutic intervention.
Yet, delivery of diverse modalities across the blood-brain barrier and to specific regions of the brain remains a challenge that limits efficacy and creates burdens on routes of administration.
Manifold has moved quickly using in vivo design to establish a brain shuttling platform and is now building a pipeline of medicines for neurological disorders with immense unmet need.
Discovery
Optimization
Partnerships
We partner around our brain shuttles as well as engineering of tissue and tumor-specificity across multiple modalities, including oligos, ADCs, and immune engagers.
Our team
With deep expertise spanning high-throughput molecular biology, ML-guided protein engineering and drug discovery we're united by a common mission: to create life-changing medicines by unlocking in vivo drug design at scale.
Founders & Leadership
